[OncoHost in Technology Networks] Addressing one of the most common dilemmas faced by oncologists

Technology Networks spoke to Dr. Ofer Sharon, CEO of OncoHost, to learn more about the challenges in NSCLC treatment, how proteomics-based analysis could enable personalized cancer treatments and the advantages of a test to predict a patient’s clinical benefit from PD-1/PD-L1 inhibitors.

Read more here.